TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05622695

Intervention type: DEVICE
Intervention: catheterization
Description: Swan-Ganz catheterization (also called right heart catheterization or pulmonary artery catheterization) is the passing of a thin tube (catheter) into the right side of the heart and the arteries leading to the lungs. It is done to monitor the heart's function and blood flow and pressures in and around the heart.
Study: NCT04555343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 1gm instilled instravesically
Study: NCT04148352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab injected every 2 weeks for 18 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected every 2 weeks for 18 weeks
Study: NCT04007926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise programme
Description: Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise programme
Description: Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
Study: NCT06506682

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint Induced Movement Therapy
Description: CIMT is an intensive upper limb therapy for children with unilateral (one sided) cerebral palsy where the child wears a constraint (splint or mit) on their dominant hand so that they use the involved (weaker) side to do activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIMT + VR
Description: Participants in the CIMT+VR group of this study protocol will do everything the CIMT group does PLUS will utilize at least 4 of the following VR technologies each day of intervention: FitMi, Tyromotion Pablo® UpperExtremity, Hocoma Armeo® Spring Pediatric, Nintendo Wii, and Parrot Drone.
Study: NCT05338996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iENGAGE for PrEP
Description: This intervention originally developed for people living with HIV (PLWH), is designed to promote engagement, retention, and adherence to treatment by addressing the social determinants of health that often act as barrier to remaining in care and achieving viral suppression. Based on our experience with this intervention we believe that it is well suited to similarly promote engagement, retention, and utilization of PrEP care among our proposed target population of WOC by a) removing barriers to care and b) addressing unmet needs by providing c) point-to-point linkage to care services delivered by multi-disciplinary teams of individuals within or outside of the health facility, and d) the use of telehealth visits to facilitate engagement in care and improve health visit attendance. The original iENGAGE is a 4-session, in-clinic behavioral intervention.
Study: NCT05638204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicidal Crisis Intervention (SCI)
Description: This study's experimental condition consisted of the Suicidal Crisis Intervention (SCI), developed by the Flemish Centre of Expertise of Suicide prevention. The SCI aims to provide tools for dealing with future suicidal crises for people after a suicidal crisis or suicide attempt. The intervention attempts to provide insight into the suicidal crisis by giving suicidality meaning within the life history. It aims to increase motivation for specialized care and therefore facilitate continuity of care. In addition, the method also wants to involve the close relative(s) of the suicidal person in the treatment. The SCI offers care providers a clear structure and handles to do this within a short period of time (4 sessions). Within the SCI are a number of crucial elements: the therapeutic relationship, involving loved ones, person-centred care, the Integrated Explanatory Model for Suicidal Behavior (Van Heeringen, 2007), the safety plan (Stanley \& Brown, 2012) and continuity of care.
Study: NCT05825170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FASY L
Description: Subjects will receive FASY L in lips at level of their scar.
Study: NCT06192641

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 3 MG
Description: patients received 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).
Study: NCT05487352

Intervention type: OTHER
Intervention: hyperglycemia exposure in the first trimester
Description: The exposure means the hyperglycemia identified by the 75g oral glucose tolerance test before the 14 weeks of gestation
Study: NCT06731530

Intervention type: DEVICE
Intervention: HD Analyzer
Description: HD Analyzer (Visiometrics, Terassa, Spain, Keeler)

Intervention type: DEVICE
Intervention: Corvis ST
Description: Corvis ST (Oculus, Germany)

Intervention type: DEVICE
Intervention: Corvis ST
Description: Corvis ST (Oculus, Germany)

Intervention type: DEVICE
Intervention: OCT-A Angiovue
Description: OCT-A Angiovue (Optovue, Inc., Fremont, California, USA)

Intervention type: DEVICE
Intervention: OCT-A Angiovue
Description: OCT-A Angiovue (Optovue, Inc., Fremont, California, USA)

Intervention type: DEVICE
Intervention: IOLMaster V.5.4
Description: IOLMaster V.5.4 (Carl Zeiss., Meditec)
Study: NCT05747287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microcatheter
Description: supports the insertion of the guide wire，exchange of the guide wire and the delivery of contrast media
Study: NCT06731530

Intervention type: DEVICE
Intervention: IOLMaster V.5.4
Description: IOLMaster V.5.4 (Carl Zeiss., Meditec)

Intervention type: DEVICE
Intervention: Topcon SP-1P
Description: Topcon SP-1P (Topcon Medical Inc., Tokyo, Japan)
Study: NCT06609928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FOLR1 CAR T-cells
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo CSF and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT06731530

Intervention type: DEVICE
Intervention: Topcon SP-1P
Description: Topcon SP-1P (Topcon Medical Inc., Tokyo, Japan)

Intervention type: OTHER
Intervention: BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus examination
Description: BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus Examination

Intervention type: OTHER
Intervention: BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus examination
Description: BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus Examination
Study: NCT06741254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: During the NST procedure (average 20-30 minutes), the pregnant woman will lie on her left side. A stress ball will be placed in the right hand of the pregnant woman. The pregnant woman will be instructed to squeeze the stress ball for 2-3 seconds and then relax the hand and arm. This process will be repeated throughout the NST.
Study: NCT06741176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The research data will be collected with mothers whose babies are in the NICU. Information about the research will be given to mothers who come to leave milk for their babies and the research will be conducted with those who agree to participate. All surveys will be pre-tested on the mothers without randomization and the group they are in will be determined by randomization. The mothers in the experimental group will be asked to write messages to their babies on the milk bags they bring in the mornings for 3 days. They will be asked to write on the paper attached to the milk bag what they want to tell their baby that the investigators will read the message to them and to return it every morning. The post-test of all surveys will be conducted at the end of the 3rd day.
Study: NCT06609928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT06741176

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The research data will be collected with mothers whose babies are in the NICU. Information about the research will be given to mothers who come to leave milk for their babies and the research will be conducted with those who agree to participate. All surveys will be pre-tested on the mothers without randomization and the group they are in will be determined by randomization. The post-tests will be conducted 3 days after the pre-test without any messages being requested from the mothers in the control group.
Study: NCT06744881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAPA-IVM
Description: On days 2-4 of the menstrual cycle, after patients have consented to CAPA-IVM, they will undergo oocyte aspiration anytime thereafter but no later than day 6 of the cycle. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 or day 5 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transfer
Study: NCT06746922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation
Description: Neuro-MS/D (Neurosoft) rTMS device will be used for stimulation with an angulated figure-of-eight coil. Neuronavigation system will be used to determine the application site. Before each session, active motor threshold (aMT) will be determined by obtaining a motor evoked potential with an amplitude of \>200μV in the EMG recording of the first dorsal interosseous muscle (FDI), which is slightly contracted (10-20% of maximum contraction) in at least five out of 10 stimuli delivered to the primary motor cortex. The handle will be held at a 45° angle to the sagittal plane, pointing backwards and laterally to create posterior-anterior current flow in the brain. The stimulation parameters are as follows:~Parameters:~Stimulation type:Burst Stimulus amplitude (% MT): 80 Burst frequency in sequence (Hz):5 Pulse frequency within burst (Hz):50 Number of bursts in the sequence: 10 Number of series:20 Interval between sequences: 8 sec Total time: 3min 47sec Total number of pulses: 600

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intermittent theta-burst stimulation
Description: In the sham application, the probe of the transcranial magnetic stimulation device will be placed in the vertical position and held perpendicular to the vertex and applied at an ineffective dose so that the patient hears the same sound. In order for the device to produce the same sound and warning sounds as the active application, it will be operated at the lowest operating power of 1 power. In the device operating at this power, there is no possibility of any warning due to the upright position of the probe.
Study: NCT06746948

Intervention type: OTHER
Intervention: dyadic psychological distress
Description: There is no intervention among the cross-sectional study.
Study: NCT06746493

Intervention type: OTHER
Intervention: Rehabilitation
Description: People after a stroke participated in a standard rehabilitation process carried out at the neurological rehabilitation department.
Study: NCT06747598

Intervention type: DIAGNOSTIC_TEST
Intervention: pregnancy test
Description: POC pregnancy testing using peripheral serum
Study: NCT06750302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methoxyflurane - Penthrox
Description: 3ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline + one drop of methoxyflurane
Study: NCT06751108

Intervention type: DRUG
Intervention: Corticosteroids (CS)
Description: Concomitant use of immune checkpoint inhibitors and corticosteroids

Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitors
Description: Non-concomitant use of corticosteroids

Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitors
Description: Non-concomitant use of corticosteroids
Study: NCT06749314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression
Description: The LE-ULBD: Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression is a single portal through lamina with instrument to decompression both side of the spinal canal, giving strength of preserve facet joint, preserve spinal musculature, mitigate the risk of adjacent fusion and lesser bleeding
Study: NCT06751355

Intervention type: DEVICE
Intervention: SkinScan3D camera
Description: The SkinScan3D (SS3D) is a portable, battery-powered imaging prototype which can successfully achieve all-focus, 3D images using low-cost, off-the-shelf components.
Study: NCT06751238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Intravenous secukinumab
Study: NCT06748092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCare IC1000
Description: Measurement of Intraocular Pressure (IOP) in sitting and supine position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCare IC200
Description: Measurement of Intraocular Pressure (IOP) in sitting and supine position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAT
Description: Measurement of Intraocular Pressure (IOP) in sitting position
Study: NCT06609928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis
Study: NCT06748092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perkins
Description: Measurement of Intraocular Pressure (IOP) in supine position
Study: NCT06750068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed space maintainer
Description: Digitally fabricated #d printed space maintainer
Study: NCT06609928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT06617169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNPR-101-PCTA-177Lu
Description: MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNPR-101-PCTA-177Lu
Description: MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNPR-101-PCTA-177Lu
Description: MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNPR-101-PCTA-177Lu
Description: MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNPR-101-PCTA-177Lu
Description: MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.
Study: NCT06627439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comadres Saludables
Description: Comadres Saludables is a web-based healthy living training for community health workers aimed at addressing obesity in Latinas. Comadres Saludables will combine both theory and evidence-based practices to provide participants with the self-efficacy, knowledge, and skills required to effectively implement an obesity intervention for Hispanic women. Participants (CHWs) will build their skillset through interactive quizzes, exercises, and video role-playing scenarios. Additionally, Comadres Saludables allows participants to utilize interactive mHealth tools to enhance implementation with Hispanic women. Participants will access the training for three months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will access the web-based HHS Promoting Healthy Choices and Community Changes that includes a variety of content via text, audio, and video. The information is designed to educate CHWs on how to implement health interventions for positive community change. They are asked to review it for three months.
Study: NCT06629701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External support for vein grafts
Description: Group A will consist of a group of patients who will be sutured with external support for vein grafts.
Study: NCT06713941

Intervention type: OTHER
Intervention: Study of the treatment
Description: Intervention Description 1 \* (Limit: 1000 characters) Study of prescribed treatments, treatments taken by the patients, and treatment discontinuation
Study: NCT06713213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow-regulated nasal oxygen delivery system (FRNDS)
Description: FRNDS is a novel cannula device that can both measure tidal volume (VT) in real time while simultaneously delivering air to the test subject.~After collecting data without any flow through the FRNDS cannula for 2 minutes, varying amounts of medical air ( 21% Fio2) starting with 2 Liters for two minutes , 4 liters for 2 minutes, 6 liters for two minutes and 8 liters for two minutes would be delivered while monitoring and recording data previously described with the FRNDS device.
Study: NCT06474546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: A diet based on the principles of the Mediterranean Diet (MedDiet): consists of an abundance of plant foods - unrefined cereals, fruit, vegetables, and extra-virgin olive oil - a moderate consumption of poultry, dairy products, eggs, and low consumption of sweets and red meats.~All subjects will be instructed to follow the MedDiet for 8 weeks by the study team. Families will be given the option to continue for 12 weeks if they wish to do so.
Study: NCT06172660

Intervention type: DRUG
Intervention: Nirsevimab
Description: Immunoprophylaxis against RSV

Intervention type: DRUG
Intervention: Nirsevimab
Description: Immunoprophylaxis against RSV

Intervention type: DRUG
Intervention: Nirsevimab
Description: Immunoprophylaxis against RSV
Study: NCT05233137

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA coaching
Description: PA coaching: Patients receive a step counter together with a coaching application (m-PAC, AppsOnly, KU Leuven) installed on a smartphone. The step counter and coaching application are connected via Bluetooth. The coaching application has the goal of PA promotion as well as detecting any new AECOPD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA coaching
Description: PA coaching: Patients receive a step counter together with a coaching application (m-PAC, AppsOnly, KU Leuven) installed on a smartphone. The step counter and coaching application are connected via Bluetooth. The coaching application has the goal of PA promotion as well as detecting any new AECOPD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Each session will include at least the following components:~* Resistance training of the lower limbs: Exercises for 6 muscle groups using minimal (e.g. ankle weights or elastic resistance bands) or no (body weight) equipment are foreseen. Each exercise will be performed in 3 series of 8 repetitions.~* Functional training: Sit to stand exercise and stair climbing. During the first 2 weeks of the exercise training program, at least 3 strength exercises and 1 functional exercise will be performed each session.~Starting from the 3rd week of the exercise training program, whole body exercise training (interval training for walking, cycling, stair climbing and high knees) will be added. From this moment on, at least 1-2 whole body exercises and 2-3 strength and functional exercises will be performed during each physiotherapy session. By doing this, each session will consist of a minimum of 4 exercises in total.
Study: NCT05737550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Previct Drugs
Description: Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
Study: NCT05664581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Acoustic Pulse
Description: Subcutaneous Rapid Acoustic Pulse Treatments
Study: NCT05554692

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic tests of cochlear implant function
Description: Because the subjects in the study will use CI devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of CI function. This will include perceptual tests of temporal discrimination and speech understanding.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic tests of auditory function
Description: The intervention here will be to carry out diagnostic tests of hearing. This will include perceptual tests of temporal discrimination and speech understanding.
Study: NCT04820621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runcaciguat (BAY1101042)
Description: Given as 1 x 15 mg modified release \[MR\] tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runcaciguat (BAY1101042)
Description: Given as 1 x 15 mg modified release \[MR\] tablet
Study: NCT06750068

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional space maintainer
Description: Stainless steel space maintains